Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies including antibody discovery technologies, ion channel discovery technology, formulation science, pseudomonas fluorescent protein expression technology, and liver targeted pro-drug technologies that help pharmaceutical and biotechnology companies in the discovery and development of medicines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focuses on the development of diagnostic imaging and therapies for oncology, blood disorders and other indications. Its major development programs include captisol-enabled (CE)-iohexol program, in Phase II for diagnostic imaging with a reduced risk of renal toxicity; luminespib/Hsp90 Inhibitor in Phase II indicated for cancer; CE-sertraline, an oral concentrate in Phase I for depression; PF530 interferon-beta in Phase I trials for immunomodulatory disease; and PF582 ranibizumab in Phase I for ocular disease. There are other preclinical programmes include It’s partnered programmes which are in late development stage such as Bendamustine for oncology, CX-01 for oncology, Fycompa for central nervous system, Ganaxalone iv for central nervous system, ML-141 for oncology, V116 for pneuococcal adult, SB206 for infectious disease, Mekinist (Ce-Trametinib) for cancer, Opt-302 for ophthalmology, CRM197 for infectious disease, Ce-Furosemide for cardiovascular disease, Vilazodone for central nervous system, Sparsentan for severe and rare, Ensifentrine (RPL554) for the treatment of respiratory disease, Teriparatide for women's health, Pradefovir for infectious disease. FLT3 Kinase Inhibitors, PF529 Pegfilgrastim, CCR1 Antagonist, CE-Busulfan for Oncology; CE-Cetirizine Injection for Allergy; CE-Silymarin for Topical formulation for Sun damage; GCSF Receptor Agonist for Blood disorders; and PF810 Recombinant Peptide for Endocrine System. In FY2022, the company spend US$36.1 million which 18.4% of company’s total revenue and has 49 employees working on its R&D activities. Ligand has over 390 issued patents for Captisol compositions worldwide including 200 granted patents for Vernalis; 200 patents and 40 pending patent applications worldwide for Pelican Expression Technology.